

Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID): Study Protocol for a Quasi-Experimental Treatment Development Study

Aaron Hogue, Molly Bobek, Nicole P. Porter, Alexandra MacLean, Craig E. Henderson, Amanda Jensen-Doss, Gary M. Diamond, Michael A. Southam-Gerow, Jill Ehrenreich-May

Submitted to: JMIR Research Protocols
on: July 15, 2024

Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript..... 5

Supplementary Files..... 51

0..... 51

Figures 52

Figure 1..... 53

Figure 2..... 54

Multimedia Appendixes 55

Multimedia Appendix 1..... 56

Multimedia Appendix 2..... 56

Multimedia Appendix 3..... 56

Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID): Study Protocol for a Quasi-Experimental Treatment Development Study

Aaron Hogue¹ PhD; Molly Bobek¹ LCSW; Nicole P. Porter¹ PhD; Alexandra MacLean¹ MA; Craig E. Henderson² PhD; Amanda Jensen-Doss³ PhD; Gary M. Diamond⁴ PhD; Michael A. Southam-Gerow⁵ PhD; Jill Ehrenreich-May³ PhD

¹Partnership to End Addiction New York US

²Sam Houston State University Huntsville US

³University of Miami Coral Gables US

⁴Ben-Gurion University of the Negev Be'er Sheva IL

⁵Virginia Commonwealth University Richmond US

Corresponding Author:

Aaron Hogue PhD

Partnership to End Addiction

711 Third Avenue, Suite 500

New York

US

Abstract

Background: Internalizing disorders (IDs), primarily depression and anxiety, are highly prevalent among adolescents receiving community-based treatment for substance use disorders (SUDs). For such clients, interventions that do not address both SUD and ID problems holistically are less effective. A few integrated behavioral models for treating SUDs and IDs in adolescents exist; however, they feature intensive manualized procedures that are can be cumbersome to scale and deliver. As a result, the adolescent SUD clinical workforce is not systematically educated or trained in evidence-based practices for IDs.

Objective: This pilot treatment development study will develop and test a modular treatment protocol for addressing co-occurring IDs among adolescents (age 13-18) enrolled in routine care for SU problems: Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID). As an adjunctive protocol, Fam-AID will not require clinicians to markedly alter existing base practices for SUD. It will be anchored by three evidence-based foundations for treating co-occurring adolescent IDs: family engagement techniques, transdiagnostic individual CBT techniques, and family psychoeducation and safety planning.

Methods: This quasi-experimental study will proceed in two stages. The Pilot Stage will use rapid cycle prototyping methods in collaboration with end-user stakeholders to draft protocol delivery and fidelity guidelines adapted from existing resources; solicit provider and client input on protocol content and delivery via cognitive interviewing; and pilot prototype components on 4-6 cases. The second stage will be an Interrupted Time Series Study for N = 60 comorbid SUD/ID cases across two sites serving diverse adolescent: 30 will receive treatment as usual (TAU), and then following clinician training in the protocol, 30 new cases will receive TAU enhanced by Fam-AID. Aim 1 will examine Fam-AID cases for protocol acceptability via therapist and client interviews along with fidelity benchmarks via therapist- and observer-report protocol fidelity data. Aim 2 will compare TAU Only versus TAU + Fam-AID for impacts on family treatment attendance and on adolescent ID and SU symptoms measured at baseline, 3-, and 6-month follow-up.

Results: Study recruitment will begin in April 2025.

Conclusions: We anticipate that Fam-AID will contain five treatment modules that can be delivered in any sequence to meet client needs: Family Engagement of primary supports in treatment planning and services; Relational Reframing of family constraints, resiliencies, and social capital connected to the adolescent's ID symptoms; Functional Analysis of the adolescent's ID symptoms and related behaviors; Cognitive-Behavioral Therapy to address the adolescent's ID symptoms and functional needs, featuring three core techniques (emotion acceptance, emotional exposure, behavioral activation) to address negative affect and emotional dysregulation; and Family Psychoeducation and Safety Planning focused on education about comorbid SUD/ID and prevention of adolescent self-harm. If shown feasible and effective, Fam-AID will offer SUD clinicians a set of pragmatic

interventions for treating co-occurring IDs in adolescent clients. Clinical Trial: ClinicalTrials.gov NCT06413979; <https://www.clinicaltrials.gov/study/NCT06413979>.

(JMIR Preprints 15/07/2024:64332)

DOI: <https://doi.org/10.2196/preprints.64332>

Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

✓ **Please make my preprint PDF available to anyone at any time (recommended).**

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.

Only make the preprint title and abstract visible.

No, I do not wish to publish my submitted manuscript as a preprint.

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible to all users.

Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in <http://www.jmir.org>, I will be able to make the full manuscript available to all users.

Original Manuscript

Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID):
Study Protocol for a Quasi-Experimental Treatment Development Study

Aaron Hogue^{a,*}

Molly Bobek^a

Nicole P. Porter^a

Alexandra MacLean^a

Craig E. Henderson^b

Amanda Jensen-Doss^c

Gary M. Diamond^d

Michael A. Southam-Gerow^e

Jill Ehrenreich-May^c

^aPartnership to End Addiction, 711 Third Avenue, 5th floor, New York, NY, 10017, USA

^bSam Houston State University, 1905 University Ave, Huntsville, TX 77340, USA

^cUniversity of Miami, 1320 S Dixie Hwy, Coral Gables, FL 33146, USA

^dBen-Gurion University of the Negev, David Ben Gurion Blvd 1, Be'er Sheva, Israel

^eVirginia Commonwealth University, 806 W. Franklin St., Richmond, VA 23284

*Corresponding author.

Email addresses: ahogue@toendaddiction.org, ORCID: 0000-0001-8365-9545 (A. Hogue);
mbobek@toendaddiction.org, ORCID ID: 0009-0007-4961-8652 (M. Bobek);
nporter@toendaddiction.org, ORCID: 0000-0001-6149-9501 (N. Porter);
amaclean@toendaddiction.org, ORCID: 0009-0004-1656-2427 (A. MacLean); CEH003@shsu.edu,
ORCID: 0000-0003-2779-8879 (C. E. Henderson); gdiamond@bgu.ac.il, ORCID ID: 0000-0003-
0781-1810 (G. M. Diamond); masouthamger@vcu.edu; ORCID ID: 0000-0002-4545-6752 (M. A.

Southam-Gerow); ajensendoss@miami.edu, ORCID: 0000-0002-1817-6122 (A. Jensen-Doss);
j.ehrenreich@miami.edu, ORCID: 0000-0001-7436-5393 (J. Ehrenreich-May).



Abstract

Background. Internalizing disorders (IDs), primarily depression and anxiety, are highly prevalent among adolescents receiving community-based treatment for substance use disorders (SUDs). For such clients, interventions that do not address both SUD and ID problems holistically are less effective. A few integrated behavioral models for treating SUDs and IDs in adolescents exist; however, they feature intensive manualized procedures that are can be cumbersome to scale and deliver. As a result, the adolescent SUD clinical workforce is not systematically educated or trained in evidence-based practices for IDs.

Objective. This pilot treatment development study will develop and test a modular treatment protocol for addressing co-occurring IDs among adolescents (age 13-18) enrolled in routine care for SU problems: *Family Support Protocol for Adolescent Internalizing Disorders* (Fam-AID). As an adjunctive protocol, Fam-AID will not require clinicians to markedly alter existing base practices for SUD. It will be anchored by three evidence-based foundations for treating co-occurring adolescent IDs: family engagement techniques, transdiagnostic individual CBT techniques, and family psychoeducation and safety planning.

Methods. This quasi-experimental study will proceed in two stages. The Pilot Stage will use rapid cycle prototyping methods in collaboration with end-user stakeholders to draft protocol delivery and fidelity guidelines adapted from existing resources; solicit provider and client input on protocol content and delivery via cognitive interviewing; and pilot prototype components on 4-6 cases. The second stage will be an Interrupted Time Series Study for N = 60 comorbid SUD/ID cases across two sites serving diverse adolescent: 30 will receive treatment as usual (TAU), and then following clinician training in the protocol, 30 new cases will receive TAU enhanced by Fam-AID. Aim 1 will examine Fam-AID cases for protocol acceptability via therapist and client interviews along with fidelity benchmarks via therapist- and observer-report protocol fidelity data. Aim 2 will compare TAU Only versus TAU + Fam-AID for impacts on family treatment attendance and on adolescent ID

and SU symptoms measured at baseline, 3-, and 6-month follow-up.

Results: Study recruitment will begin in April 2025.

Conclusion. We anticipate that Fam-AID will contain five treatment modules that can be delivered in any sequence to meet client needs: *Family Engagement* of primary supports in treatment planning and services; *Relational Reframing* of family constraints, resiliencies, and social capital connected to the adolescent's ID symptoms; *Functional Analysis* of the adolescent's ID symptoms and related behaviors; *Cognitive-Behavioral Therapy* to address the adolescent's ID symptoms and functional needs, featuring three core techniques (emotion acceptance, emotional exposure, behavioral activation) to address negative affect and emotional dysregulation; and *Family Psychoeducation and Safety Planning* focused on education about comorbid SUD/ID and prevention of adolescent self-harm. If shown feasible and effective, Fam-AID will offer SUD clinicians a set of pragmatic interventions for treating co-occurring IDs in adolescent clients.

Trial registration: Trial Registration: ClinicalTrials.gov NCT06413979;
<https://www.clinicaltrials.gov/study/NCT06413979>.

Keywords: adolescent substance use, adolescent anxiety and depression, co-occurring disorders, adjunctive treatment, family-based interventions, usual care

Introduction

Anxiety and Depression among Adolescents with SUD: Highly Prevalent and Disruptive

Anxiety (including trauma-related problems) and depression are highly prevalent among adolescents who misuse substances. National and community surveys report that adolescents with substance use disorders (SUDs) have comorbidity rates ranging between 17% – 30% for an anxiety disorder, major depressive disorder, or both ([1]). Comorbidity is even higher in clinical samples. Adolescents enrolled in SUD treatment have cooccurrence rates ranging from 22% – 26% for anxiety disorders and 24% – 50% for depression disorders, along with an alarming range of 55% – 70% for clinically elevated symptoms of either disorder [2, 3]. Anxiety and depression diagnoses themselves cooccur at such high rates in adolescents that prevailing clinical taxonomies place them within a single category of “internalizing disorder” (ID) whose core symptoms—anxious emotional states, depressed mood, somatization, social withdrawal—are associated with over-controlled behaviors and subjective distress. According to the tripartite model of comorbidity, the strong cooccurrence of anxiety and depression symptoms constitute a shared internalizing syndrome, *negative affectivity*, which is linked to other internalizing symptoms such as low positive affect and anxious arousal [4-6]. In this vein, developmental theories describe an internalizing pathway to SUD whereby childhood behavioral challenges marked by negative affectivity and social inhibition predispose adolescents to SU problems[7, 8].

Longitudinal outcome data suggest that adolescents with cooccurring SUD/ID are more difficult to treat effectively than those who do not have IDs. One systematic review [9] found that adolescents with comorbid SUD and depression showed higher attrition from treatment, and generally worse outcomes for both SU and depression, than those with a singular disorder. Another [10] reported that baseline levels of elevated ID symptoms broadly, or diagnosis of an anxiety or depression disorder, predicted worse SU outcomes. Studies have also shown that maintenance of SUD treatment gains [11, 12] and posttreatment recovery to adaptive levels of functioning [13] are

harder to achieve for adolescents with IDs and related negative affect. It also appears that ID-related symptoms impact posttreatment SU behavior in multiple ways, foremost being that negative affect can induce adolescents to reinitiate use ([14]) and/or interfere with their motivation and capacity to utilize relapse prevention and health promotion skills learned during treatment [15].

Usual Care for Adolescent SUD: Sizable Gaps in Evidence-based Treatment Planning for ID

A recent SAMHSA resource guide on adolescents with serious emotional disorders and co-occurring SU [16] asserts that integrated planning for adolescent SUD/ID is routinely inaccessible due to several factors, including broad service fragmentation as well as limited cross-training for both SU and mental health clinicians; moreover, few clinicians have specialized training in both disorders. Clinicians with specialty licenses to treat SUD are typically required to obtain only generic training in cooccurring disorders; they do not receive systematic training in IDs, nor certified training in evidence-base practices for ID ([17]). Surveys of the adolescent SUD specialty workforce confirm this ID services gap ([18, 19]). One study [20] found that whereas only 10% of SUD clinicians reported using specific protocols to treat SUD/ID, 97% indicated they would use such a protocol, and moreover, could devote eight workday hours to train in it.

Integrated Treatment Models for Comorbid SUD/ID: Major Barriers to Implementation

One strategy to promote treatment planning and training for SUD/ID is to disseminate integrated treatment models that contain two components: one targeting SUD, the other targeting ID. However, because integrated models of this kind require multidomain symptom targeting and intervention coordination, they are difficult to implement and evaluate [21]. To date, only a few integrated models for adolescent SUD/ID have been tested in randomized trials. Esposito-Smythers et al. [22] showed effects for a protocol containing cognitive-behavioral therapy (CBT) for SUD, individual CBT for depression and suicidality, and family skills training. Rohde et al. [23] varied treatment delivery sequence for adolescents with SUD and depression, finding that family therapy for SUD followed by CBT for depression was most effective for SU and depression outcomes

combined, compared to a CBT-first model and a simultaneous family-and-CBT model. Goldston et al. [24] found that a protocol grounded in CBT and relapse prevention for SUD, depression, and suicidal behavior outperformed usual care. Two other manualized models [25-27] integrate family and individual CBT interventions for SUD and ID, including posttraumatic stress disorder, and a handful of studies have examined brief interventions targeting both SU and ID in adolescents [28].

Unfortunately, none of the integrated models targeting adolescent SUD/ID has been scaled to widespread use. One category of scalability barriers pertains to *characteristics of the behavioral health system*. As mentioned, clinicians with specialty SUD licenses typically have little training or clinical support in addressing IDs. Factors related to clinician training, site licensing, and healthcare regulation all contribute to this deficiency [16, 29]. As a result, adolescent SUD clinicians are generally not familiar with evidence-based ID interventions nor clinically prepared to deliver them [20, 30]. This deficiency reflects a broader and longstanding service fragmentation problem in this country—mental health and SU treatment systems are largely siloed from one another—that ill-serves the needs of adolescents with cooccurring problems[31, 32]. A second category of scalability barriers pertains to *characteristics of integrated models*. The integrated SUD/ID models previously described share basic structural features with the larger phylum of manualized behavioral models. Manualized models typically feature structured intervention sequencing and wholesale implementation of treatment components. In contrast, community clinicians favor piecemeal implementation and selective treatment planning, including flexible use of techniques as adjunctive interventions for cases with complex diagnoses [33, 34]. Manualized models also contain extensive quality procedures to facilitate therapist training, fidelity, and ongoing certification. Such procedures are difficult to sustain due to vicissitudes in regulatory practices, decrease in agency stamina to honor quality methods for extended periods, and demoralization when external experts manage quality control [35].

Promising Solution to Overcoming Implementation Barriers: Core Elements Strategy

Due to formidable implementation barriers, it will not be sufficient to become more proficient at disseminating and training the SUD workforce to utilize integrated models for SUD/ID. Likewise, it will not be enough to more efficiently disseminate and train SUD clinicians in manualized models for adolescent depression, anxiety, or both—all the same barriers to widespread scalability loom. An alternative strategy to advance scalability of evidence-based treatments is to focus on core elements that are common across models for similar populations. The core elements strategy defines reduced sets of specific techniques that are common, active ingredients in multiple treatments for a given disorder [34, 36]. This strategy offers implementation advantages in two key domains: *Modularity*: Core elements can be more easily learned and retained by trainees; delivered as modular units or as a sequence of discrete interventions; and flexibly selected and coordinated to address diverse, comorbid, and/or emerging clinical problems [37, 38]. *Sustainability*: They promote clinician judgment, coupled with broad guidelines, to flexibly select interventions to fit client profiles [39]; provide strategies to select interventions for comorbid clients for whom no dedicated manuals exist [37, 40]; and avail a few intervention modules to apply across numerous clients [34, 36]. Core elements have proven feasible to scale in routine settings [37, 41, 42]; moreover, core elements can perform on equal footing with manualized treatments across an array of adolescent outcomes [41, 43, 44].

Core Elements for Targeting IDs among Adolescents with SUD/ID: Three Foundations

In line with the core elements strategy, this study is developing a core elements protocol designed to treat ID symptoms among adolescents with SUD in usual care. It combines several existing treatment techniques, most of which have empirical support for addressing treatment targets related to adolescent ID, into a single modular protocol: *Family Support Protocol for Adolescent Internalizing Disorders* (Fam-AID). As depicted in Figure 1, intervention selection is guided by three broad evidence-based principles for treating adolescent SUD/ID:

Engage the Family System. In order to enhance adolescent readiness to participate in behavioral treatment of any kind, it is highly advantageous to engage parents and other family members actively [45]. Research-based family engagement interventions for an array of adolescent services include emphasizing the role of family involvement in services, anticipating how family resources and dynamics could impact participation, building alliances with multiple family members, and managing family interactions during initial clinical encounters [46]. Specific to adolescents, evidence-based interventions for engaging families include systemic family engagement [47-49], which focuses on recognizing incompatible agendas of family members, and how this reduces the likelihood of any member attending; identifying who can act as a reliable family messenger, and who has power to influence other members to attend; and providing rationale for treatment that accounts for concerns of key members. An engagement strategy unique to family-based treatment is relational reframing [50, 51], which involves efforts to transform symptom- or person-focused perceptions of clinical problems into an understanding of those problems as having important, fundamentally relational aspects [52-55].

Deliver Transdiagnostic Interventions for ID. Adolescents with elevated ID levels often have underlying emotional vulnerabilities in three areas: negative emotional reactivity, in the form of more frequent experiences of intense negative emotions and less flexible reactions to these; affect intolerance, such that emotional experiences are perceived as difficult to endure; and emotional avoidance, wherein adolescent respond to affect intolerance with efforts to suppress, avoid, or otherwise control uncomfortable feelings [56, 57]. Therefore, interventions for adolescent ID need to target high levels of negative affect, distress intolerance, and affect avoidance. An efficient approach for treating these overlapping vulnerabilities is to use transdiagnostic interventions, which treat similar behavior problems (eg, anxiety and depression) via interventions targeting higher-order precipitating processes (eg, emotion dysregulation) [58, 59]. Transdiagnostic interventions have proven efficacious for adolescents with IDs in multiple-baseline, open, and randomized trials [60-

63], producing improvements in depression, anxiety, and emotion dysregulation symptoms [60, 61, 64]. Ideally, transdiagnostic interventions for ID symptoms among adolescents with comorbid SUD/ID should be guided by functional assessment of the adolescent's specific ID-related impairments [21], which facilitates treatment customization by narrowing the field of available techniques to those specifically indicated for the client [65-67]. Of the several transdiagnostic techniques available for adolescent ID, three appear most salient for addressing factors that also predispose SU among adolescents: *Emotion Acceptance*, which targets emotional regulation and distress tolerance and also enhances inhibitory learning during exposure [60, 61, 68, 69]; *Emotional Exposure*, a primary driver of positive effects for adolescent anxiety [70]; and *Behavioral Activation*, a primary driver of positive effects for adolescent depression [71].

Reinforce the Family Safety Net. An essential component of comprehensive treatment planning for adolescents with SUD/ID is accounting for potential self-harm, suicidal ideation, and suicidal behavior, which often occur among adolescents with clinically elevated ID levels, especially when there is cooccurring SUD [72, 73]. Adolescents and their families can be educated together about potential self-injurious behaviors and invited to co-create safety plans [74]. Although single-session adolescent-only safety contracts are not routinely effective, more intensive safety planning involving families can reduce self-harming behavior in adolescents [75]. Moreover, family members can be sources of recovery capital to help adolescents sustain reductions in SUD and ID symptoms.

Specific Aims of the Study

In Year 1, this study will develop a Fam-AID implementation toolkit during a three-part *Pilot Stage* at one pilot site: (a) solicit provider input on Fam-AID components; (b) create video-based training and fidelity procedures, leveraging the research team's existing training and consultation resources in both core family-based interventions [76, 77] and adolescent-focused transdiagnostic techniques [78] for adolescent behavior problems; (c) pilot the toolkit with 4-6 clients. In Years 2-3, this study will conduct an *Interrupted Time Series* evaluation for N = 60 adolescent SUD/ID cases

across two sites serving diverse clients: 30 will receive treatment as usual (TAU), and then following clinician training, 30 new cases will receive TAU enhanced by Fam-AID.

This protocol development study has two specific aims: *Aim 1: Protocol Feasibility*. In the Fam-AID condition only, the study will evaluate: (a) Protocol acceptability via client and therapist qualitative interviews; (b) Fidelity benchmarks via therapist- and observer-report fidelity measures of protocol coverage (Is each module delivered in at least one session?) and protocol dose (Is the average module extensiveness score greater than the mean of the fidelity measure?). *Aim 2: Protocol Outcomes*. In comparing TAU Only versus TAU + Fam-AID, the study will examine protocols impacts on (a) family member session attendance via clinic logs and (b) adolescent ID-related symptoms (emotion regulation, depression, anxiety), SU, and family communication about SUD/ID at 3-month and 6-month follow-up. Overall, these pilot-scale protocol viability and impact findings, if promising, will set the stage for a randomized trial to examine Fam-AID effects on immediate and ultimate outcomes in a larger community sample.

Methods

Ethics Approval

Pilot Stage: 3-Phase Clinical Protocol Compilation Procedures

At *Project Initiation* (months 1-2) the study team will review 3 clinical protocols and companion training resources they collectively produced: (a) archive of empirically distilled core family therapy treatment techniques for adolescent SUD [51]; (b) adjunctive family-based protocols for targeting cooccurring Attention-Deficit/Hyperactivity Disorder among adolescents with primary SUD [79, 80]; and the Unified Protocol for Adolescents for transdiagnostic CBT interventions for adolescent ID [60, 78, 81]. The team will converge these resources to create prototype components for the 5 Fam-AID modules. They will then launch the Pilot Stage, a 3-phase stakeholder-informed process to develop Fam-AID prototype components into a beta protocol. Pilot Phase work will

follow procedures of rapid cycle prototyping that utilize mini-pilots to test early versions of protocols, combined with ongoing feedback from content experts and other stakeholders, to learn how to best design new strategies [82, 83].

During *Pilot Phase 1* (study months 3-5), the study team will conduct in-depth interviews with clinic staff and families (adolescent and caregivers) at one pilot site, with 3 primary goals. First, they will interview both staff and families about existing barriers and potential facilitators to engaging caregivers in site services. Though evidence-based interventions exist for engaging families in adolescent services—and these will be systematically incorporated in Fam-AID Module 1—such interventions are rarely used in routine care. To help prepare Module 1 for this challenge, the team will apply their expertise in this area ([84]) to identify and investigate engagement barriers (logistic, attitudinal, institutional) and generate pragmatic strategies to solve or ameliorate barriers and enhance both family motivation and intention to participate and site policies to facilitate family involvement. This information will feed forward into Pilot Phase 2 and Phase 3 activities and ultimately into the design of the new protocol. Second, the team will confer with site administrators and staff to obtain feedback on proposed clinical and fidelity strategies for: engaging the family system via culturally attuned engagement strategies and relational reframing of the adolescent's ID symptoms; delivering transdiagnostic interventions for adolescent ID via in-session functional analysis of ID symptoms followed by selection of CBT techniques for ID; and reinforce the family safety net via family-based psychoeducation about SUD/ID symptoms and long-term safety planning interventions related to adolescent self-harm. Third, they will interview 3-4 adolescents and families to canvass their knowledge, attitudes, social influences, and personal experiences related to SUD and ID services, with emphasis on perceived barriers and facilitators to integrated treatment planning for ID symptoms. The milestones for Pilot Phase 1 completion will be collaborative team-clinic consensus on initial drafts of enhanced family engagement strategies, overall protocol content, and training and implementation materials for the projected five Fam-AID modules.

During *Pilot Phase 2* (months 6-11), guided by Phase 1 results, the team will finalize modifications to Fam-AID component prototypes. They will subject prototype materials to cognitive interviewing [85] with staff and clients at the Pilot site, during which respondents will be asked to think aloud when answering questions about components. Cognitive interviewing is used to refine procedures by assessing respondent comprehension, what is meant by a particular response, and whether additional content is needed to complete a process. This phase will also focus on usability testing of protocol and implementation materials to ensure they are user friendly and efficient in delivering specified interventions [86, 87]. The milestones for Pilot Phase 2 completion will be rapid-cycle consensus on modifications to Fam-AID prototype components, resulting in a beta protocol that accounts for barriers and facilitators to delivery in routine care, to be vetted in Pilot Phase 3.

During *Pilot Phase 3* (months 12-14), the team will pilot the beta Fam-AID version by delivering components to 2-3 clients, successively adjusting component prototypes across clients and sessions, to tweak module design and troubleshoot clinical and technological features. They will then finalize component prototypes via culminating interviews with staff and clients to vet feasibility, utility, and resource requirements; this will help with empirical optimization of delivery parameters (dose, frequency, and sequencing benchmarks). The milestone for Pilot Phase 3 completion is rapid-cycle finalization of components constituting the Fam-AID modules.

Interrupted Time Series: Study Design

Following completion of the Pilot Stage, the team will conduct an interrupted time series study featuring quasi-experimental pilot effectiveness research methods to evaluate the Fam-AID protocol and implementation toolkit [88]. Figure 2 depicts the basic design and timeline of the interrupted times series study. The quasi-experimental interrupted time series with nonequivalent groups—which tracks target data both before and after introducing a programmatic change to a group whose membership may vary over time—is appropriate for testing viability and impacts of

new interventions delivered in field settings [89-91]. This design is functionally similar to a posttest-only design with a nonequivalent historical control group. Two partner clinic sites will be involved to reduce confounds from site-specific implementation effects and increase diversity in clients and therapists. Aim 1 methods will feature procedures designed for Stage 1 treatment development [92, 93] to establish proof-of-concept (acceptability, fidelity benchmarks) for the protocol and toolkit. Aim 2 methods will examine Fam-AID impact on family member attendance in treatment and client outcomes (adolescent ID symptoms, adolescent SU, parent-adolescent communication about SUD/ID).

Study Sites and Participants

Both study sites are licensed to deliver SUD services to adolescents. Neither currently supports an evidence-based treatment protocol that specifically targets IDs. Participant eligibility criteria are: (1) Adolescent is age 13–18. (2) Adolescent lives with a primary caregiver who can attend treatment sessions. (3) Adolescent endorses one or more Diagnostic and Statistical Manual [94] symptoms for SUD and meets American Society of Addiction Medicine criteria for outpatient SU treatment. (4) Adolescent meets DSM-5-TR criteria, or has elevated symptoms and impairment, for an ID, with the following expected to be most common: Current or Recurrent Major Depressive Episode, Pervasive Depressive Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder, Panic Disorder, Posttraumatic Stress Disorder. (5) Adolescent completes intake and is enrolled as an active case at study site. Adolescent exclusion criteria are: illness requiring hospitalization; current psychotic symptoms; severe SU problems that require immediate relief (detox or residential placement); pervasive developmental disorder. To match real-world care, no eligibility criteria or other study directives will pertain to medication status. Assessment data collected during previous studies in the same regions [80, 95] provide the following adolescent demographic projections: average age 16.2 years; Male 42/60 (70%), Female 18/60 (30%); Black 9/60 (15%), Latinx 24/60 (40%), White Non-Latinx 24/60 (40%), Other 3/60 (5%). Prevalence rates of diagnosed adolescent

IDs in the historical referral streams across sites are: 45% with a depression diagnosis (Current or Recurrent Major Depressive Episode; Pervasive Depressive Disorder), 24% with Generalized Anxiety Disorder, and 18% with Posttraumatic Stress Disorder.

Study Condition: TAU Only

Previous research on TAU intervention delivery at both study sites using therapist self-report [96] and observational data from session recordings [97] indicates that site therapists routinely deliver relatively low-dose quantities of evidence-based SUD treatment techniques, favoring motivational interviewing and addiction counseling techniques, with even less delivery of CBT or family therapy techniques for SUD. Sites do not have existing protocols for treating IDs as either main referral problems or cooccurring conditions.

Study Condition: TAU + Fam-AID

Fam-AID will contain 5 modular components to be delivered in any order and to the extent indicated based on case status [37, 43, 98]. Modules can be individually or collectively completed in one session, staggered across sessions, and interspersed with other interventions. The time needed to complete each module will vary based on client profile, practice habits of the provider, and case progress. Fam-AID will have standardized options for versatile delivery with individual adolescents alone whenever family members cannot be engaged in services: Modules 3 and 4 can proceed intact, and Module 5 can be adjusted for adolescent-only delivery. The study will be halted if it appears that Fam-AID delivery induces clinical harm. The following is a description of projected module content, noting that the ultimate set of modules and their content will be determined over the course of the study:

Module 1: Culturally Attuned Family Engagement. To promote family engagement, clinicians collaborate with members by instilling hope and involving them in goals related to ID problems. They encourage members to attend sessions throughout care, present treatment as an opportunity to talk about new issues or old issues in new ways, joins with members by showing respect and

validation, and use relevant self-disclosure to establish connections [99-101]. Engagement is guided by principles of cultural attunement [102], which include accentuating values and strengths minimized in dominant culture, remaining accountable for how interventions disrupt or reinforce existing inequities, and encouraging members to make conscious choices about how they frame their identities and respond to injustice.

Module 2: Relational Reframing of ID Symptoms. Clinicians use relational reframing techniques to shift the focus of treatment from exclusively fixing adolescents and their symptoms to improving the quality of adolescent-family relations. They assert treatment should be grounded in acknowledging, understanding, and repairing relationship problems as a means of addressing adolescent ID problems and bolstering individual and family recovery paths. Basic approaches to delivering a relational reframe for adolescent IDs include: identify sequences of behaviors or emotions involving families that precede or directly cause identified problems; focus on the impact that ID-related problems have on the thoughts, feelings, and behaviors of both adolescent and family; and champion relational repair or improvement [52-55].

Module 3: Functional Analysis of ID Symptoms. Clinicians use functional analysis to uncover information about reinforcers of symptoms to render interventions personally relevant, as well as help adolescents and families understand behavioral chains of antecedents and consequences that maintain problems. Functional analysis steps for adolescent ID include [103-105]: articulate scenarios in which ID-related problems occur; examine circumstances that precede problems, ascertaining both internal and external antecedents; identify short-term positive outcomes as well as long-term negative outcomes; and engage clients in comparing positive versus negative consequences. Clinicians are careful to validate feelings that emerge, reflect appreciation for client sharing, and maintain a stance of curiosity about the perceived value of behaviors and an empathic position in exploring healthier alternatives.

Module 4: CBT Treatment Techniques for ID. Clinicians consult data from functional analysis of ID symptoms to select from among a menu of three transdiagnostic CBT techniques with evidence for treating both depression and anxiety in teens [106, 107]. In Emotion Acceptance, adolescents develop skills for noticing and accepting their emotions, including unpleasant and/or strong emotions [60, 61, 68, 69], which help reduce anxiety sensitivity. They learn skills of present-moment and nonjudgmental awareness, which can increase affect tolerance [108]. In both Emotional Exposure and Behavioral Activation, adolescents are helped to approach situations, thoughts, and/or triggers that elicit strong emotions that have been previously avoided [60, 61, 69, 103, 105, 109, 110]. They try out various “opposite” actions to their typical emotional responses or behaviors (eg, volunteering to speak in class) to increase distress tolerance. Adolescents are encouraged to employ new skills to fully engage in situations eliciting strong emotions and maintain clarity about the purpose of the opposite actions they select. All 3 techniques operate primarily on an approach versus avoidance clinical mechanism, so that they can synergistically reinforce (ie, act as agonists for) one another.

Module 5: SUD/ID Education and Safety Planning. Clinicians use family decision coaching [80, 111, 112] to converse with family members about 3 overlapping pathways of SUD and ID cooccurrence [10, 113-115]: (a) Self-medication: ID precedes the onset of SUD, and substances are valued for psychoactive properties that alleviate ID symptoms; (b) SU exposure: SUD precedes the onset of ID and creates developmental lag in the emergence of self-regulatory functions which precipitate ID and, if severe, impair neurocognitive functioning; (c) Shared etiology: SUD and ID are mutually influencing axes of dysregulation that compromise healthy development. Family SUD/ID education transitions to family-based safety planning about both nonsuicidal self-injury and suicide ideation and attempts, guidelines for which focus on establishing physical and psychological safety, identifying strategies that can be used instead of self-harm, and identifying individuals to whom the adolescent can go for help [74, 75, 116, 117].

Fam-AID Training and Fidelity Monitoring

Site clinicians will be trained during six hours featuring video-based training [118, 119] in Fam-AID modules and techniques. Thereafter, consultation at each site will include twice-monthly live consultation with a protocol expert focused on equipoise between protocol fidelity and case tailoring, along with continuous feedback from therapist- and observer-report fidelity data emailed directly to clinicians and used in live consultation to enable rapid adjustment in protocol delivery [120-122]. Two main fidelity benchmarks will be monitored for each case: Clinicians deliver interventions for every module in at least one treatment session (ie, coverage); and clinicians perform at or above the mean scale score for intervention extensiveness on the Fam-AID Fidelity Checklist (described in Study Measures) for at least one technique from each module (ie, dose), with both therapist- and observer-report Checklist versions being tracked.

Study Procedures

All full-time therapists at both study sites who volunteer to participate will be consented. We project 4 therapists at each site ($N = 8$) will participate. As in the authors' previous work [80], clinic staff will determine client eligibility ($N = 60$) during intake procedures. IDs will be assessed using the MINI-KID [123, 124], a structured diagnostic interview administered by lay interviewers that yields DSM-5-TR categories and has been used in diverse adolescent samples [80, 125]. Families of adolescents who meet eligibility criteria will be asked by clinic staff to consent to allow the study team to contact them to arrange informed consent. Clients will be consented to audio-record sessions, complete outcome interviews and questionnaires, and grant access to clinic records. Client data on protocol viability (Fam-AID cases only) and clinical outcomes will then be collected on all study clients (regardless of amount of treatment participation) at baseline, 3-month, and 6-month follow-up using REDCap Cloud software, a widely used secure, HIPAA-compliant, web-based data collection platform.

Clinicians in both conditions will be asked to complete a self-report fidelity measure after every session with a study client and audio record all sessions, a minimally intrusive procedure

widely accepted by families and therapists in previous work [95]. Data will be collected using web-based Qualtrics links and uploaded to secure servers. Per the study team's numerous observational fidelity studies [126-130], one session will be randomly selected from the Early phase of treatment (sessions 1-3) and two from the Later phase (sessions 4+) of each client for coding with an observational version of the Fam-AID Fidelity Checklist (described in Study Measures). Fidelity observational coders will be trained by the study team via gold-standard procedures [126, 131-133] and kept naive to study condition.

Study Measures

Fam-AID Fidelity Checklist. This study will use an adapted version of the Inventory of Therapy Techniques (ITT; [96, 97]), a post-session therapist-report fidelity tool that requires 1–2 minutes to complete. ITT items each measure the extensiveness (ie, thoroughness and frequency) with which a given treatment technique was used on a 3-point Likert-type scale: 0 (Not at all), 1 (A little bit/Moderately), 2 (Quite a bit/Extensively). ITT items derive from treatment protocols and their companion observational fidelity tools—for example, [51] for family therapy and [67] for CBT—after being vetted for relevance by community clinicians in multiple treatment settings [134]. The ITT has shown strong construct [50, 134] and predictive [80, 135] validity in studies with adolescents receiving family therapy and CBT in usual care. The Fam-AID Fidelity Checklist mimics the ITT structure, containing multiple items in each of the 5 Fam-AID modules: Culturally Attuned Family Engagement, Relational Reframing of ID Symptoms, Functional Analysis of ID Symptoms, CBT Treatment Techniques for ID, and SUD/ID Education and Safety Planning. The Fam-AID Fidelity Checklist—Observer Version is an identical measure with instructions for observer coding.

Protocol Acceptability. Protocol acceptability interviews will be held with therapists and clients who participate in the Fam-AID protocol. Therapists will be interviewed in agency-based focus groups. Clients will be interviewed at the 6-month follow-up assessment point; adolescents and

caregivers will be interviewed separately. Interview content will be adapted from existing treatment feasibility and acceptability interviews (see [136]) and include questions such as: *Overall impressions of Fam-AID for use in routine practice* (Therapist; open-ended), *How effective and/or difficult was it to use Fam-AID for your cases compared to usual practice?* (Therapist; Likert-type rating); *Was it important for you (your caregiver) to be included in treatment?* (Client; open-ended); *How much did emotion coping training help you (your child)?* (Client; Likert-type rating).

Adolescent and Family Outcomes. Clinical record data will be collected on the number of treatment sessions attended by family members, along with data on adolescent attendance. *Difficulties in Emotion Regulation Scale* [137, 138] is a 16-item measure of 6 aspects of emotion regulation: nonacceptance, engagement in goal-directed activities, impulsivity, emotional awareness, access to emotion regulation strategies, and emotional clarity. It uses a 5-point Likert scale and has shown acceptable test-retest reliability and internal consistency in adolescent populations [137-140]. *Revised Children's Anxiety and Depression Scale-Child and Parent Report* (RCADS-C/P [141]) is a 47-item measure of an adolescent's anxiety and depressive symptoms. RCADS-C contains 6 DSM-linked subscales: Separation Anxiety, Social Anxiety, Generalized Anxiety, Obsessive-Compulsive Disorder, Panic Disorder, and Major Depressive Disorder (MDD). A Total Anxiety subscale score sums 37 items from the 5 anxiety subscales; the MDD subscale score sums 10 items. RCADS-P is identical to the RCADS-C, but the wording of the items is from the parents' perspective. RCADS-C/P have exhibited strong and acceptable internal consistency, respectively [142-144]. *CRAFFT* [145, 146] is a widely used and well validated adolescent-report tool that measures patient use of alcohol, cannabis, nicotine, illegal drugs, prescription medication, or anything else to get high in the past year and the past 3 months. It also asks about riding in a Car driven by someone (including self) who was intoxicated. If SU is reported, the tool asks 5 additional questions: use to Relax, use while Alone, Forget things you did while intoxicated, Family or friends tell you to reduce use, gotten into Trouble while using. *Parent-Teen SUD/ID Communication Frequency* [147] is a 6-item adolescent and

caregiver report of how often parents and teens talk to one another about key SUD-ID issues (eg, health risks of SU/ID; discipline regarding SU) scored on a 5-point scale from never to very often (see [78-80]). *Parent-Teen SUD/ID Communication Quality* [148] is a 6-item adolescent and caregiver report of the quality of communication between parent and adolescent about SUD/ID issues (eg, *my caregiver/child and I are interested in each other's opinions about SUD/ID; if my caregiver/child and I talk about SUD/ID, I feel understood*) scored on a 5-point scale from not at all to very much (see [147, 149]).

Plan of Analyses

Aim 1 Acceptability analyses (Fam-AID condition only) will explore protocol acceptability and perceived effectiveness via formative qualitative interviews with staff and clients. Interviews will be recorded, transcribed, and then analyzed inductively [150] for data relevant to feasibility and acceptability. Two research staff members will separately code interviews for emerging concepts using thematic content analysis [151], an approach that applies inductive coding to identify themes within the data. Initial analysis will identify concepts through open coding [152]; inter-rater reliability checks will then be used to compare themes generated and resolve conflicts, and coding will continue to point of saturation, that is, when no new concepts emerge.

Aim 1 Fidelity Benchmarks analyses (Fam-AID condition only) will examine both types of fidelity metrics previously described. *Coverage*: Descriptive statistics will capture frequencies related to (a) proportion of clients who received at least 1 intervention from each of the 5 Modules; and (b) which interventions from which Modules were most or least favored across clients. Chi-square analysis will be used to compare study conditions on the proportion of clients who received adequate coverage, and one-way analysis of variance to assess mean differences across modules in the Fam-AID condition to evaluate module preferences among therapists. *Dose*: Statistical equivalence testing [153] will be used to examine whether clinicians' average scores for intervention extensiveness on both observer- and therapist-report versions of the Fam-AID Fidelity Checklist are

equivalent to a designated benchmark, which will be set (granting appropriate latitude for a pilot trial) for each Module as: $M = 2.5$, $SD = 0.50$. A confidence interval approach will be adopted in which an equivalence interval (EI) is defined as the benchmark plus or minus 10%. Next, a confidence interval (CI) is defined by this formula: $CI_{90\%} = M_R - M_T \pm z_{\alpha}(S_{MR-MT})$. In this equation M_R represents the benchmark Module mean, M_T the average Module score for study therapists, z_{α} the critical one-tailed value from the z distribution for the chosen value of α , and S_{MR-MT} the pooled standard error. If the calculated CI falls within the EI, equivalence can be concluded. Also, therapist variability in Fam-AID fidelity will be examined via statistical process control analyses (see [125]) in which individual therapist fidelity scores are plotted on a control chart to check for meaningful variation compared to control limits represented by the designated fidelity benchmark.

Aim 2a Family Attendance will involve between-condition comparison of treatment sessions attended by family members other than the adolescent. Linear mixed-effects (LME) modeling will be used to examine the effect of Condition on attendance counts. The model will include fixed effects for independent variables (ie, Condition) and random effects to account for nesting at Therapist level, thereby providing unbiased parameter estimates [154, 155]. Nesting at Client level will not need to be controlled in these analyses, as client summed totals will serve as a dependent measure: Tallies of sessions attended by family members will be summed across the follow-up period. The Linear Mixed Effects (LME) Models package [156] in R [157] will be used; it provides full information maximum likelihood estimation (MLE) and restricted MLE, both of which produce unbiased parameter estimates under the assumption that data are missing at random (MAR) and outperform other missing data approaches even when MAR is not met [158]. Effect sizes will be indexed by Eta squared (η^2) and generated via the effectsize package [159]. However, the nonlinear mixed effects model (nlme) will be employed if the assumption of continuous data is not tenable (eg, attendance counts are not normally distributed).

Aim 2b Adolescent and Family Outcomes analyses will involve similar LME models previously described. To test for change over time, each model will include fixed effects for time (months since baseline, coded as 0, 3, 6) and random effects for (1) nesting of clients within therapists and (2) repeated measures within person across follow-up. Hypotheses will be tested by adding Condition as a fixed effect and examining the Condition-by-time interaction on each outcome in separate models. Acknowledging that outcomes may not demonstrate sharp trajectory change during the relatively brief 6-month follow-up window, the intercept will be set at the terminal assessment point by re-coding timepoints (-6, -3, 0); in doing so, the Condition effect for the intercept will reflect a between-group difference at 6-month follow-up. LME modeling is recommended as an alternative to traditional modeling techniques for longitudinal designs with small samples [160].

Study Power

Aim 2 analyses will compare study conditions on family attendance and client outcomes over time with Client ($N = 60$) as unit of analysis. Power analysis was conducted using the software GPower, which permits good facsimile to the current design given the lack of specific parameter estimates to simulate power directly and lacking a strong analogue for cluster (Therapist). Assuming $\alpha = .05$, a total sample $N = 60$ with 30 clients per condition, 3 measurement occasions moderately intercorrelated ($r = .50$), and a moderate effect size of $d = 0.60$, yielded power = .80. A smaller effect size of $d = 0.50$ yielded power = .65, assuming $\alpha = .05$. These estimates are in line with impacts seen in studies of adolescent with ID but not SUD [62, 161] and studies of adolescents with SU problems treated in usual care [80, 95].

Ethics Approval

Ethical approval for this trial is pending from Solutions IRB. All study activities will be subject to monitoring by the Data Safety and Monitoring Board (DSMB) of the same institution (see Appendix 2). Any modifications to the protocol that might impact the conduct of the study or its

specified objectives and procedures will require a formal amendment to the protocol and approval by the IRB and DSMB prior to implementation. Adolescents and caregivers will independently provide informed assent/consent prior to initiation of study activities (see Appendix 1). As reimbursement for interview completion, each participant receives US \$110 total in gift card vouchers of their choice via Tango Card: US \$30 each for baseline and US \$40 each at 3- and 6-month follow-up. All assessment data will be automatically downloaded from the web-based data collection portal into a secure database maintained in a secure firewall- and password-protected location on a data network. All network data are backed up daily. Only project staff will have direct access to the data. All standard procedures for data management and security will be followed. For planned statistical analyses, database managers will extract data from the REDCap repository and create data files with a .csv format, and all participant identifiers stripped that will be provided to statisticians for analysis.

Results

This study is being conducted over a 3-year period. Participant recruitment and data collection will begin in April 2025. We expect results from this study to be published in 2027.

Discussion

This pilot treatment development study will test feasibility (acceptability and fidelity) and short-term client outcomes (adolescent ID symptoms, adolescent SU, family communication about SUD/ID) of a modular protocol for addressing co-occurring IDs among adolescents with SU in routine care. Fam-AID will contain five modules that can be delivered in any sequence to meet client needs: *Family Engagement* in treatment planning and services; *Relational Reframing* of family constraints, resiliencies, and social capital connected to the adolescent's ID symptoms; *Functional Analysis* of ID symptoms and related behaviors; *Cognitive-Behavioral Therapy* to address ID symptoms and functional needs; and *Family Psychoeducation and Safety Planning* focused on education about comorbid SUD/ID and prevention of adolescent self-harm. If shown feasible and

effective, Fam-AID will offer SUD clinicians a set of pragmatic interventions for treating co-occurring IDs in adolescent clients.

Importantly, Fam-AID is not intended to contain components that directly target SUD outcomes—that is, it is designed as an adjunctive intervention to complement and enhance whatever current SUD interventions are already being practiced by a given clinician or agency. The value of adjunctive protocols such as Fam-AID is to augment the overall effectiveness of care by addressing prominent cooccurring problems that, if untreated, derail treatment goals for a primary problem. The adjunctive nature of Fam-AID is a key asset for scalability: Clinicians are not asked to exchange or markedly alter their base practices for SUD.

Fam-AID contains 5 modules, each consisting of core treatment techniques that have a strong evidence base. In keeping with principles of modular intervention design [36, 162, 163], clinicians are invited to select and implement any Fam-AID module, in any order, based on client needs, with a default of delivering them sequentially. The 5 Fam-AID modules are intended to galvanize and reinforce the family support system, and equip the individual adolescent, to cope with and ameliorate ID problems. Notably, Module 4 draws its menu of core CBT techniques to treat ID-related problems (emotion acceptance, emotional exposure, behavioral activation) from an existing evidence-based transdiagnostic protocol for adolescent IDs that treats underlying negative affect and emotional dysregulation [78]. In these ways, Fam-AID is distinct from other adolescent SUD/ID options due to how it combines a core elements strategy, family-focused interventions, and individual CBT techniques—which might enhance the often modest long-term impact of interventions for ID symptoms in usual care [164].

Fam-AID contains 3 additional innovations intended to boost treatment effectiveness for this highly vulnerable group and enhance the feasibility of implementing protocol modules in routine SUD care. First, in line with the core elements strategy, it is intended for use by invested clinicians of any clinical orientation and training background. To be sure, Modules 1 and 2 contain techniques

drawn from the family therapy approach, whereas Modules 3 and 4 techniques derive from CBT. Even so, Fam-AID modules are constructed as basic, step-by-step clinical practice guides that can be adopted and deployed by even entry-level clinicians. Second, it uses evidence-based family engagement techniques to systematically integrate caregivers in the treatment process. Families are not typically centralized in SUD services for adolescent [165] despite the compelling empirical rationale that family-based treatment is a first-line option for adolescent SUD [166], is well-established for adolescent depression [167], and is a useful adjunct for adolescent anxiety [168]. Third, it contains a customization feature in which selected CBT techniques are integrated into treatment planning based on a functional ID assessment completed in session. In what amounts to a small-scale version of treatment tailoring [66, 169], clients and therapists can collaboratively choose which of 3 CBT techniques (emotion acceptance, emotional exposure, behavioral activation) is best suited to address the adolescent's ID symptoms.

Study Design Limitations and Strengths

Due to the very small number of sites, clinicians, and clients in this study, results will not be generalizable to the broad network of adolescent SUD treatment clinics or SUD clinical workforce. Randomized designs, which provide control against unknown study confounds and allow for reasonable assumptions of causality related to manipulated variables even in small samples, are generally preferable to quasi-experimental interrupted time series designs. However, we decided against using a randomized design for many reasons. It would result in half as many therapists being trained in Fam-AID, which in a small-scale study exacerbates between-therapist variability in protocol fidelity that could dilute proposed effects, and reduces therapist generalizability [88, 170]. Also, it introduces potential for between-condition bleed from training procedures that could nullify protocol effects. Also, to the degree that usual practices in the study sites (representing the TAU condition) already feature some type of ID-targeted interventions, the interrupted time series design is credibly stringent. This design was also vastly preferred by our partner clinics, as it allows all staff

to receive Fam-AID training. Importantly, this design can yield hypothesized viability and impact effects even if routine treatment services for SUD are basically inert at either or both study sites.

Reproducibility and Dissemination Plans

The Fam-AID protocol will be developed to maximize its reproducibility and scalability by featuring a clinically flexible, modular design buttressed by core element techniques. If study aims are met, the foundation will be laid to test Fam-AID at R01-level scale. Study information and findings will be disseminated through publication of journal articles, presentations at relevant conferences, and reports to relevant stakeholders. If the Fam-AID protocol ultimately demonstrates feasibility and effectiveness, we will use existing state- and national-level clinician training and licensing platforms to ensure the protocol and its companion fidelity tools and procedures are made widely available to agencies and practitioners who serve youth with SUD.

Declarations

Acknowledgments: The authors would like to thank Mari Watkins for their assistance in preparing the manuscript. No generative Artificial Intelligence was used in any portion of manuscript generation or preparation.

Funding Statement: This work was supported by a grant from the National Institute on Drug Abuse (R34DA056026; PI: Hogue). Preparation of this manuscript was also supported by the Family Involvement in Recovery Support and Treatment Research Network, which is co-funded by the National Institute on Drug Abuse and National Institute of Neurological Disorders and Stroke (R24DA051946; PI: Hogue). All statements in this report are solely those of the authors and do not necessarily represent the official views of the National Institutes of Health.

Conflict of Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data Availability: The datasets generated and analyzed during the current study will be archived online via the National Institute on Drug Abuse Data Archive.

Author Contributions: Hogue, Bobek, Diamond, and Ehrenreich-May authored the conceptualization and clinical content of the Fam-AID model; Hogue, Porter, MacLean, and Southam-Gerow authored the study design, measures, and procedures; and Hogue, Henderson, and Jensen-Doss authored the statistical approach, main study analyses, and study power.

See Appendix 3 for the completed SPIRIT Checklist for this study protocol.

Abbreviations

CBT: cognitive-behavioral therapy

DSMB: Data Safety and Monitoring Board

Fam-AID: Family Support Protocol for Adolescent Internalizing Disorders

ID: internalizing disorder

IRB: Institutional Review Board

ITT: Inventory of Therapy Techniques

LME: linear mixed effects

MDD: Major Depressive Disorder

MAR: missing at random

MLE: maximum likelihood estimation

RCADS-C/P: Revised Children's Anxiety and Depression Scale-Child/Parent Report

SUD: substance use disorder

TAU: treatment as usual

Multimedia Appendix 1: Sample Consent Form for Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID): Study Protocol for a Quasi-Experimental Treatment Development Study.



Multimedia Appendix 2: Study Committees/Teams for Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID): Study Protocol for a Quasi-Experimental Treatment Development Study.



Multimedia Appendix 3: SPIRIT Checklist for Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID): Study Protocol for a Quasi-Experimental Treatment Development Study.



References

1. Lu, W., et al., *Trends and disparities in treatment for co-occurring major depression and substance use disorders among US adolescents from 2011 to 2019*. JAMA Network Open, 2021. **4**(10): p. e2130280-e2130280.
2. Chan, Y.-F., M.L. Dennis, and R.R. Funk, *Prevalence and comorbidity of major internalizing and externalizing problems among adolescents and adults presenting to substance abuse treatment*. Journal of substance abuse treatment, 2008. **34**(1): p. 14-24.
3. Tims, F., et al., *Characteristics and problems of 600 adolescent cannabis abusers in outpatient treatment*. Addiction, 2002. **97**(S1): p. 46-57.
4. De Bolle, M. and F. De Fruyt, *The tripartite model in childhood and adolescence: Future directions for developmental research*. Child Development Perspectives, 2010. **4**(3): p. 174-180.
5. Conway, C.C., et al., *Core dimensions of anxiety and depression change independently during adolescence*. Journal of abnormal psychology, 2017. **126**(2): p. 160.
6. Van Beveren, M.-L., et al., *Joint contributions of negative emotionality, positive emotionality, and effortful control on depressive symptoms in youth*. Journal of Clinical Child & Adolescent Psychology, 2019. **48**(1): p. 131-142.
7. Hussong, A.M., et al., *A systematic review of the unique prospective association of negative affect symptoms and adolescent substance use controlling for externalizing symptoms*. Psychology of Addictive Behaviors, 2017. **31**(2): p. 137.
8. Trucco, E.M., S.A. Hartmann, and N. Fallah-Sohy, *Charting a course for empowered adolescent substance use treatment*. 2024.
9. Babowitch, J.D. and K.M. Antshel, *Adolescent treatment outcomes for comorbid depression and substance misuse: A systematic review and synthesis of the literature*. Journal of Affective Disorders, 2016. **201**: p. 25-33.
10. Curry, J.F. and J. Hersh, *Depressive disorders and substance use disorders*. Youth substance abuse and co-occurring disorders, 2016: p. 131-156.
11. Cornelius, J.R., et al., *Rapid relapse generally follows treatment for substance use disorders among adolescents*. Addictive behaviors, 2003. **28**(2): p. 381-386.
12. Cornelius, J.R., et al., *Major depression associated with earlier alcohol relapse in treated teens with AUD*. Addictive behaviors, 2004. **29**(5): p. 1035-1038.
13. Santisteban, D.A., et al., *The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial*. Psychiatric rehabilitation journal, 2015. **38**(1): p. 55.
14. Ramo, D.E. and S.A. Brown, *Classes of substance abuse relapse situations: a comparison of adolescents and adults*. Psychology of Addictive Behaviors, 2008. **22**(3): p. 372.
15. Chung, T. and S.A. Maisto, *Relapse to alcohol and other drug use in treated adolescents: Review and reconsideration of relapse as a change point in clinical course*. Clinical Psychology Review, 2006. **26**(2): p. 149-161.
16. (SAMHSA), S.A.a.M.H.S.A., *Treatment Considerations for Youth and Young Adults with Serious Emotional Disturbances/Serious Mental Illnesses and Co-occurring Substance Use*. 2021, Substance Abuse and Mental Health Services Administration,; Rockville, MD:: National Mental Health and Substance Use Policy Laboratory.
17. Wisconsin, S.o. Department of Safety and Professional Services (DSPS) Substance Abuse Counselor. 2023; Available from: <https://dsps.wi.gov/Pages/Professions/SubstanceAbuseCounselor/Default.aspx>.
18. Adams, Z.W., et al., *Clinician perspectives on treating adolescents with co-occurring post-traumatic stress disorder, substance use, and other problems*. Journal of child & adolescent substance abuse, 2016. **25**(6): p. 575-583.

19. Barrett, E.L., et al., *Service provider perspectives on treating adolescents with co-occurring PTSD and substance use: challenges and rewards*. *Advances in Dual Diagnosis*, 2019. **12**(4): p. 173-183.
20. Lichtenstein, D.P., A. Spirito, and R.P. Zimmermann, *Assessing and treating co-occurring disorders in adolescents: examining typical practice of community-based mental health and substance use treatment providers*. *Community mental health journal*, 2010. **46**(3): p. 252-257.
21. Hulvershorn, L.A., P.D. Quinn, and E.L. Scott, *Treatment of adolescent substance use disorders and co-occurring internalizing disorders: A critical review and proposed model*. *Current drug abuse reviews*, 2015. **8**(1): p. 41-49.
22. Esposito-Smythers, C., et al., *Treatment of co-occurring substance abuse and suicidality among adolescents: a randomized trial*. *Journal of consulting and clinical psychology*, 2011. **79**(6): p. 728.
23. Rohde, P., et al., *Sequenced versus coordinated treatment for adolescents with comorbid symptoms and substance use disorders*. *Journal of Consulting & Clinical Psychology*, 2014. **82**: p. 342-348.
24. Goldston, D.B., et al., *Feasibility of an integrated treatment approach for youth with depression, suicide attempts, and substance use problems*. *Evidence-based practice in child and adolescent mental health*, 2021. **6**(2): p. 155-172.
25. Sheidow, A.J., et al., *Randomized controlled trial of an integrated family-based treatment for adolescents presenting to community mental health centers*. *Community mental health journal*, 2020: p. 1-17.
26. Hahn, A.M., et al., *Risk reduction through family therapy (RRFT): Protocol of a randomized controlled efficacy trial of an integrative treatment for co-occurring substance use problems and posttraumatic stress disorder symptoms in adolescents who have experienced interpersonal violence and other traumatic events*. *Contemporary clinical trials*, 2020. **93**: p. 106012.
27. Danielson, C.K., et al., *Safety and efficacy of Exposure-Based risk reduction through family therapy for co-occurring substance use problems and posttraumatic stress disorder symptoms among adolescents: a randomized clinical trial*. *JAMA psychiatry*, 2020. **77**(6): p. 574-586.
28. McDanal, R., et al., *Effects of Brief Interventions on Internalizing Symptoms and Substance Use in Youth: A Systematic Review*. *Clinical child and family psychology review*, 2022. **25**(2): p. 339-355.
29. Sterling, S., et al., *Access to treatment for adolescents with substance use and co-occurring disorders: challenges and opportunities*. *Journal of the American Academy of Child & Adolescent Psychiatry*, 2010. **49**(7): p. 637-646.
30. Hinckley, J.D. and P. Riggs, *Integrated treatment of adolescents with co-occurring depression and substance use disorder*. *Child and Adolescent Psychiatric Clinics*, 2019. **28**(3): p. 461-472.
31. Hawkins, E.H., *A tale of two systems: Co-occurring mental health and substance abuse disorders treatment for adolescents*. *Annual review of psychology*, 2009. **60**(1): p. 197-227.
32. Welsh, J.W., et al., *Narrative Review: Revised Principles and Practice Recommendations for Adolescent Substance Use Treatment and Policy*. *Journal of the American Academy of Child and Adolescent Psychiatry* 2024.
33. Carroll, K.M. and B.J. Rounsaville, *Behavioral Therapies: The glass would be half full if only we had a glass*, in *Rethinking Substance Abuse: What the Science Shows and What We Should Do About It*, W.R. Miller and K.M. Carroll, Editors. 2006, Guilford Press: New York.
34. Garland, A.F., et al., *Identifying common, core elements of evidence-based practice for children with disruptive behavior disorder*. *Journal of the American Academy of Child & Adolescent Psychiatry*, 2008. **47**: p. 505-514.

35. Ametaj, A.A., et al., *A preliminary investigation of provider attitudes toward a transdiagnostic treatment: Outcomes from training workshops with the unified protocol*. Administration and Policy in Mental Health and Mental Health Services Research, 2021. **48**: p. 668-682.
36. Chorpita, B.F., E. Daleiden, and J. Weisz, *Identifying and selecting the common elements of evidence based interventions: A distillation and matching model*. Mental Health Services Research, 2005. **7**(1): p. 5-20.
37. Weisz, J.R., et al., *Testing standard and modular designs for psychotherapy treating depression, anxiety, and conduct problems in youth: A randomized effectiveness trial*. Archives of General Psychiatry, 2012. **69**(3): p. 274-82.
38. Ward, A.M., et al., *Tracking evidence based practice with youth: validity of the MATCH and standard manual consultation records*. Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53, 2013. **42**(1): p. 44-55.
39. Chorpita, B.F. and E.L. Daleiden, *Mapping evidence-based treatments for children and adolescents: Application of the distillation and matching model to 615 treatments from 322 randomized trials*. Journal of Consulting & Clinical Psychology, 2009. **77**: p. 566-579.
40. Gallo, K. and D. Barlow, *Factors involved in clinician adoption and nonadoption of evidence-based interventions in mental health*. Clinical Psychology: Science and Practice, 2012. **19**(1): p. 93-106.
41. Chorpita, B.F., et al., *Child STEPs in California: A cluster randomized effectiveness trial comparing modular treatment with community implemented treatment for youth with anxiety, depression, conduct problems, or traumatic stress*. Journal of Consulting & Clinical Psychology, 2017. **85**: p. 13-25.
42. Weisz, J.R., et al., *Initial test of a principle-guided approach to transdiagnostic psychotherapy with children and adolescents*. Journal of Clinical Child & Adolescent Psychology, 2017. **46**: p. 44-58.
43. Chorpita, B.F., et al., *Long-term outcomes for the Child STEPs randomized effectiveness trial: A comparison of modular and standard treatment designs with usual care*. Journal of consulting and clinical psychology, 2013. **81**(6): p. 999-1009.
44. Weisz, J.R., et al., *When the torch is passed, does the flame still burn? Testing a "train the supervisor" model for the Child STEPs treatment program*. Journal of consulting and clinical psychology, 2018. **86**(9): p. 726.
45. Becker, K.D. and B.F. Chorpita, *Future Directions in Youth and Family Treatment Engagement: Finishing the Bridge Between Science and Service*. Journal of Clinical Child & Adolescent Psychology, 2023: p. 1-26.
46. Chorpita, B.F. and K.D. Becker, *Dimensions of treatment engagement among youth and caregivers: Structural validity of the REACH framework*. Journal of Consulting and Clinical Psychology, 2022. **90**(3): p. 258.
47. Szapocznik, J., et al., *Engaging adolescent drug abusers and their families in treatment: A strategic structural systems approach*. Journal of Consulting & Clinical Psychology, 1988. **56**: p. 552-557.
48. Coatsworth, J.D., et al., *Brief strategic family therapy versus community control: Engagement, retention, and an exploration of the moderating role of adolescent symptom severity*. Family Process, 2001. **40**(3): p. 313-332.
49. Santisteban, D.A., et al., *Efficacy of Intervention for Engaging Youth and Families into Treatment and Some Variables That May Contribute to Differential Effectiveness*. Journal of Family Psychology, 1996. **10**(1): p. 35-44.
50. Hogue, A., et al., *Distilling the core elements of family therapy for adolescent substance use: Conceptual and empirical solutions*. Journal of Child & Adolescent Substance Abuse, 2017.

- 26(6): p. 437-453.
51. Hogue, A., et al., *Core Elements of Family Therapy for Adolescent Behavior Problems: Empirical Distillation of Three Manualized Treatments*. Journal of Clinical Child & Adolescent Psychology, 2019. **48**(1): p. 29-41.
 52. Narkiss-Guez, T., et al., *Intensifying attachment-related sadness and decreasing anger intensity among individuals suffering from unresolved anger: The role of relational reframe followed by empty-chair interventions*. Counselling Psychology Quarterly, 2015. **28**(1): p. 44-56.
 53. Moran, G., G.M. Diamond, and G.S. Diamond, *The relational reframe and parents' problem constructions in attachment-based family therapy*. Psychotherapy Research, 2005. **15**(3): p. 226-235.
 54. Minuchin, S. and H.C. Fishman, *Family Therapy Techniques*. 1981, Cambridge, MA: Harvard University.
 55. Szapocznik, J. and O.E. Hervis, *Brief strategic family therapy*. 2020: American Psychological Association.
 56. Barlow, D.H., et al., *The nature, diagnosis, and treatment of neuroticism: Back to the future*. Clinical Psychological Science, 2014. **2**(3): p. 344-365.
 57. Sauer-Zavala, S., J.G. Wilner, and D.H. Barlow, *Addressing neuroticism in psychological treatment*. Personality Disorders: Theory, Research, and Treatment, 2017. **8**(3): p. 191.
 58. McHugh, R., H. Murray, and D.H. Barlow, *Balancing fidelity and adaptation in the dissemination of empirically supported treatments: The promise of transdiagnostic interventions*. Behavior Research and Therapy, 2009. **47**: p. 946-953.
 59. Martin, P., et al., *Transdiagnostic treatment approaches for greater public health impact: Implementing principles of evidence-based mental health interventions*. Clinical Psychology: Science and Practice, 2018. **25**(4): p. e12270.
 60. Ehrenreich-May, J., et al., *An initial waitlist-controlled trial of the unified protocol for the treatment of emotional disorders in adolescents*. J Anxiety Disord, 2017. **46**: p. 46-55.
 61. Ehrenreich, J.T., et al., *Development of a unified protocol for the treatment of emotional disorders in youth*. Child & Family Behavior Therapy, 2009. **31**(1): p. 20-37.
 62. Queen, A.H., D.H. Barlow, and J. Ehrenreich-May, *The trajectories of adolescent anxiety and depressive symptoms over the course of a transdiagnostic treatment*. Journal of Anxiety Disorders, 2014. **28**(6): p. 511-521.
 63. Trosper, S.E., et al., *Emotion regulation in youth with emotional disorders: Implications for a unified treatment approach*. Clinical Child and Family Psychology Review, 2009. **12**(3): p. 234-254.
 64. Ehrenreich-May, J., et al., *The Unified Protocols for the treatment of emotional disorders in children and adolescents*, in *Transdiagnostic Treatments for Children and Adolescents Principles and Practice*, J. Ehrenreich-May and B.C. Chu, Editors. 2014, Guilford Press: New York, NY. p. 267-293.
 65. Brewer, S., M.D. Godley, and L.A. Hulvershorn, *Treating Mental Health and Substance Use Disorders in Adolescents: What Is on the Menu?* Current psychiatry reports, 2017. **19**(1): p. 5.
 66. Christon, L.M., B.D. McLeod, and A. Jensen-Doss, *Evidence-based assessment meets evidence-based treatment: An approach to science-informed case conceptualization*. Cognitive and Behavioral Practice, 2015. **22**(1): p. 36-48.
 67. Hogue, A., et al., *Core elements of CBT for adolescent conduct and substance use problems: Developmental psychopathology, clinical techniques, and case examples*. Cognitive and Behavioral Practice, 2020.
 68. Johnson, C., et al., *Effectiveness of a school-based mindfulness program for transdiagnostic prevention in young adolescents*. Behaviour Research and Therapy, 2016. **81**: p. 1-11.
 69. Ehrenreich-May, J., et al., *The unified protocols for the treatment of emotional disorders in*

- children and adolescents. *Transdiagnostic treatments for children and adolescents: Principles and practice*, 2013: p. 267-292.
70. Schopf, K., et al., *The role of exposure in the treatment of anxiety in children and adolescents: protocol of a systematic review and meta-analysis*. *Systematic reviews*, 2020. **9**(1): p. 1-6.
 71. Martin, F. and T. Oliver, *Behavioral activation for children and adolescents: a systematic review of progress and promise*. *European child & adolescent psychiatry*, 2019. **28**(4): p. 427-441.
 72. Hawton, K., K.E. Saunders, and R.C. O'Connor, *Self-harm and suicide in adolescents*. *The Lancet*, 2012. **379**(9834): p. 2373-2382.
 73. Moller, C.I., R.J. Tait, and D.G. Byrne, *Deliberate self-harm, substance use, and negative affect in nonclinical samples: a systematic review*. *Substance Abuse*, 2013. **34**(2): p. 188-207.
 74. Westers, N.J. and P.L. Plener, *Managing risk and self-harm: Keeping young people safe*. *Clinical child psychology and psychiatry*, 2020. **25**(3): p. 610-624.
 75. Aggarwal, S. and G. Patton, *Engaging families in the management of adolescent self-harm*. *Evidence-based mental health*, 2018. **21**(1): p. 16-22.
 76. Hogue, A., et al., *Pilot trial of online measurement training and feedback in family therapy for adolescent behavior problems*. *Journal of Clinical Child and Adolescent Psychology*, 2023.
 77. Hogue, A., et al., *Training Community Therapists in Core Elements of CBT and Family Therapy for Adolescent Externalizing Problems*. 2023: p. 1-17.
 78. Sherman, J.A. and J. Ehrenreich-May, *Changes in risk factors during the unified protocol for transdiagnostic treatment of emotional disorders in adolescents*. *Behavior Therapy*, 2020. **51**(6): p. 869-881.
 79. Hogue, A., S.W. Evans, and F.R. Levin, *A Clinician's Guide to Co-occurring ADHD Among Adolescent Substance Users: Comorbidity, Neurodevelopmental Risk, and Evidence-Based Treatment Options*. *Journal of Child & Adolescent Substance Abuse*, 2017. **26**(4): p. 277-292.
 80. Hogue, A., et al., *Randomized Trial of Academic Training and Medication Decision-Making for Adolescents with ADHD in Usual Care*. *J Clin Child Adolesc Psychol*, 2021. **50**(6): p. 874-887.
 81. Ehrenreich-May, J., et al., *Unified protocols for transdiagnostic treatment of emotional disorders in children and adolescents: therapist guide*. 2017: Oxford University Press.
 82. Beidas, R.S., et al., *Transforming mental health delivery through behavioral economics and implementation science: Protocol for three exploratory projects*. *JMIR research protocols*, 2019. **8**(2): p. e12121.
 83. Asch, D.A. and R. Rosin, *Innovation as discipline, not fad*. *N Engl J Med*, 2015. **373**(7): p. 592-594.
 84. Hogue, A., et al., *Family involvement in treatment and recovery for substance use disorders among transition-age youth: Research bedrocks and opportunities*. *Journal of Substance Abuse Treatment*, 2021. **129**: p. 108402.
 85. Willis, G.B., *Cognitive Interviewing: A Tool for Improving Questionnaire Design*. 2005, Thousand Oaks, CA: Sage Publications.
 86. Rubin, J. and D. Chisnell, *Handbook of usability testing: how to plan, design and conduct effective tests*. 2008: John Wiley & Sons.
 87. Albert, W. and T. Tullis, *Measuring the user experience: collecting, analyzing, and presenting usability metrics*. 2013: Newnes.
 88. Handley, M.A., et al., *Selecting and improving quasi-experimental designs in effectiveness and implementation research*. *Annual review of public health*, 2018. **39**: p. 5-25.
 89. Cook, T. and D. Campbell, *Quasi-Experimentation: Design and Analysis Issues for Field Settings*. 1979, Boston: Houghton-Mifflin.

90. Bernal, J.L., S. Cummins, and A. Gasparrini, *Interrupted time series regression for the evaluation of public health interventions: a tutorial*. International journal of epidemiology, 2017. **46**(1): p. 348-355.
91. Ramsay, C.R., et al., *Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies*. International journal of technology assessment in health care, 2003. **19**(4): p. 613-623.
92. Carroll, K.M. and K. Nuro, *One size cannot fit all: A stage model for psychotherapy manual development*. Clinical Psychology Science and Practice, 2002. **9**: p. 396-406.
93. Rounsaville, B.J., K.M. Carroll, and L.S. Onken, *A stage model of behavioral therapies research: Getting started and moving on from stage I*. Clinical Psychology Science and Practice, 2001. **8**: p. 133-142.
94. American Psychiatric Association, *Understanding Mental Disorders: Your Guide to DSM-5-TR®*. 2023: American Psychiatric Pub.
95. Hogue, A., et al., *Randomized trial of family therapy versus non-family treatment for adolescent behavior problems in usual care*. Journal of Clinical Child & Adolescent Psychology, 2015. **44**(6): p. 954-969.
96. Hogue, A., et al., *Reliability of therapist self-report on treatment targets and focus in family-based intervention*. Administration and Policy in Mental Health and Mental Health Services Research, 2014. **41**: p. 497-705.
97. Hogue, A., et al., *Validity of therapist self-report ratings of fidelity to evidence-based practices for adolescent behavior problems: Correspondence between therapists and observers*. Administration and Policy in Mental Health and Mental Health Services Research, 2015. **42**: p. 229-243.
98. Chorpita, B.F. and J.R. Weisz, *Modular approach to therapy for children with anxiety, depression, trauma, or conduct problems (MATCH-ADTC)*. Proprietary material: http://www.practicewise.com/portals/0/MATCH_public/index.html, 2009.
99. Dakof, G., et al., *A randomized pilot study of the Engaging Moms program for family drug court*. Journal of Substance Abuse Treatment, 2010. **38**: p. 263-274.
100. Shelef, K., G. Diamond, and H. Liddle, *Adolescent and parent alliance and treatment outcome in multidimensional family therapy*. Journal of Consulting & Clinical Psychology, 2005. **73**: p. 689-698.
101. Rowe, C.L. and H.A. Liddle, *When the levee breaks: Treating adolescents and families in the aftermath of Hurricane Katrina*. Journal of Marital and Family Therapy, 2008. **34**(2): p. 132-148.
102. McDowell, T., C. Knudson-Martin, and J.M. Bermudez, *Socioculturally attuned family therapy: Guidelines for equitable theory and practice*. 2017: Routledge.
103. Chu, B.C., et al., *An initial description and pilot of group behavioral activation therapy for anxious and depressed youth*. Cognitive and Behavioral Practice, 2009. **16**(4): p. 408-419.
104. Kanter, J.W., et al., *Toward a comprehensive functional analysis of depressive behavior: Five environmental factors and a possible sixth and seventh*. International Journal of Behavioral Consultation and Therapy, 2011. **7**(1): p. 5.
105. McCauley, E., et al., *The adolescent behavioral activation program: Adapting behavioral activation as a treatment for depression in adolescence*. Journal of Clinical Child & Adolescent Psychology, 2016. **45**(3): p. 291-304.
106. Ehrenreich-May, J. and B.C. Chu, *Overview of transdiagnostic mechanisms and treatments for youth psychopathology*. Transdiagnostic treatments for children and adolescents: Principles and practices, 2013: p. 3-14.
107. Newby, J.M., et al., *Systematic review and meta-analysis of transdiagnostic psychological treatments for anxiety and depressive disorders in adulthood*. Clinical psychology review, 2015. **40**: p. 91-110.

108. Linehan, M.M., *Cognitive behavioural therapy of borderline personality disorder*. New York: Guilford, 1993.
109. Chen, J., et al., *Behavioural activation: A pilot trial of transdiagnostic treatment for excessive worry*. Behaviour Research and Therapy, 2013. **51**(9): p. 533-539.
110. Chu, B.C., et al., *Transdiagnostic group behavioral activation and exposure therapy for youth anxiety and depression: Initial randomized controlled trial*. Behaviour research and therapy, 2016. **76**: p. 65-75.
111. Langer, D.A. and A. Jensen-Doss, *Shared decision-making in youth mental health care: using the evidence to plan treatments collaboratively*. Journal of Clinical Child & Adolescent Psychology, 2018. **47**(5): p. 821-831.
112. Davis, C.C., et al., *Putting Families in the Center: Family Perspectives on Decision Making and ADHD and Implications for ADHD Care*. Journal of attention disorders, 2012. **16**(8): p. 675-684.
113. Swendsen, J.D. and K.R. Merikangas, *The comorbidity of depression and substance use disorders*. Clinical psychology review, 2000. **20**(2): p. 173-189.
114. Trim, R.S., et al., *The relation between adolescent substance use and young adult internalizing symptoms: findings from a high-risk longitudinal sample*. Psychology of Addictive Behaviors, 2007. **21**(1): p. 97.
115. O'Neil, K.A., B.T. Conner, and P.C. Kendall, *Internalizing disorders and substance use disorders in youth: Comorbidity, risk, temporal order, and implications for intervention*. Clinical psychology review, 2011. **31**(1): p. 104-112.
116. Ougrin, D., et al., *Practitioner review: Self-harm in adolescents*. Journal of child psychology and psychiatry, 2012. **53**(4): p. 337-350.
117. Asarnow, J.R., et al., *Suicide, Self-Harm, & Traumatic Stress Exposure: A Trauma-Informed Approach to the Evaluation and Management of Suicide Risk*. Evidence-Based Practice in Child and Adolescent Mental Health, 2020. **5**(4): p. 483-500.
118. Hogue, A., et al., *Measurement Training and Feedback System for Implementation of family-based services for adolescent substance use: protocol for a cluster randomized trial of two implementation strategies*. Implementation Science, 2019. **14**(25): p. 1-12.
119. Hogue, A., et al., *Measurement Training and Feedback System for Implementation of evidence-based treatment for adolescent externalizing problems: Protocol for a randomized trial of pragmatic clinician training*. Trials, 2020.
120. Hogue, A., et al., *Making fidelity an intramural game: Localizing quality assurance procedures to promote sustainability of evidence-based practices in usual care*. Clinical Psychology: Science and Practice, 2013. **20**(1): p. 60-77.
121. Sheidow, A.J., et al., *Development of an Audiotape Review System for Supporting Adherence to an Evidence-Based Treatment*. Professional Psychology, Research and Practice, 2008. **39**(5): p. 553-560.
122. Caron, E. and M. Dozier, *Effects of fidelity-focused consultation on clinicians' implementation: an exploratory multiple baseline design*. Administration and Policy in Mental Health and Mental Health Services Research, 2019. **46**(4): p. 445-457.
123. Duncan, L., et al., *Psychometric evaluation of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)*. Psychological assessment, 2018. **30**(7): p. 916.
124. Sheehan, D.V., et al., *Reliability and validity of the mini international neuropsychiatric interview for children and adolescents (MINI-KID)*. The Journal of clinical psychiatry, 2010.
125. Hogue, A. and S. Dauber, *Assessing fidelity to evidence-based practices in usual care: the example of family therapy for adolescent behavior problems*. Evaluation and Program Planning, 2013. **37**: p. 21-30.
126. Hogue, A., et al., *Treatment techniques and outcomes in multidimensional family therapy for*

- adolescent behavior problems. *Journal of Family Psychology*, 2006. **20**: p. 535-543.
127. Hogue, A., et al., *Treatment adherence and differentiation in individual versus family therapy for adolescent substance abuse*. *Journal of Counseling Psychology*, 1998. **45**(1): p. 104-114.
 128. Hogue, A., et al., *Linking session focus to treatment outcome in evidence-based treatments for adolescent substance abuse*. *Psychotherapy: Theory, Research, Practice, & Training*, 2004. **41**: p. 83-96.
 129. Hogue, A., et al., *Assessing fidelity in individual and family therapy for adolescent substance abuse*. *Journal of Substance Abuse Treatment*, 2008. **35**: p. 137-147.
 130. Hogue, A., et al., *Treatment adherence, competence, and outcome in individual and family therapy for adolescent behavior problems*. *Journal of Consulting & Clinical Psychology*, 2008. **76**: p. 544-555.
 131. Carroll, K.M., et al., *Internal Validity of Project MATCH Treatments: Discriminability and Integrity*. *Journal of Consulting and Clinical Psychology*, 1998. **66**(2): p. 290-303.
 132. Hill, C.E., K.E. O'Grady, and I. Elkin, *Applying the collaborative study psychotherapy rating scale to rate therapist adherence in cognitive-behavior therapy, interpersonal therapy, and clinical management*. *Journal of Consulting & Clinical Psychology*, 1992. **60**: p. 73-79.
 133. Weisman, A., et al., *Evaluating therapist competency and adherence to behavioral family management with bipolar patients*. *Family Process*, 1998. **37**: p. 107-121.
 134. Hogue, A., S. Dauber, and C. Henderson, *Therapist self-report of evidence-based practices in usual care for adolescent behavior problems: Factor and construct validity*. *Administration and Policy in Mental Health*, 2014. **41**(1): p. 126-139.
 135. Henderson, C.E., A. Hogue, and S. Dauber, *Family therapy techniques and one-year clinical outcomes among adolescents in usual care for behavior problems*. *Journal of consulting and clinical psychology*, 2019. **87**(3): p. 308.
 136. Cho, E., et al., *A second and third look at FIRST: Testing adaptations of a principle-guided youth psychotherapy*. *Journal of Clinical Child & Adolescent Psychology*, 2020: p. 1-14.
 137. Bjureberg, J., et al., *Development and validation of a brief version of the difficulties in emotion regulation scale: the DERS-16*. *Journal of psychopathology and behavioral assessment*, 2016. **38**: p. 284-296.
 138. Gratz, K.L. and L. Roemer, *Multidimensional assessment of emotion regulation and dysregulation: Development, factor structure, and initial validation of the difficulties in emotion regulation scale*. *Journal of Psychopathology and Behavioral Assessment*, 2004. **26**(1): p. 41-54.
 139. Gratz, K.L. and J.G. Gunderson, *Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder*. *Behav Ther*, 2006. **37**(1): p. 25-35.
 140. Kaufman, E.A., et al., *The Difficulties in Emotion Regulation Scale Short Form (DERS-SF): Validation and replication in adolescent and adult samples*. *Journal of psychopathology and behavioral assessment*, 2016. **38**: p. 443-455.
 141. Chorpita, B.F., et al., *Assessment of symptoms of DSM-IV anxiety and depression in children: A revised child anxiety and depression scale*. *Behaviour research and therapy*, 2000. **38**(8): p. 835-855.
 142. Chorpita, B.F., C.E. Moffitt, and J. Gray, *Psychometric properties of the Revised Child Anxiety and Depression Scale in a clinical sample*. *Behaviour research and therapy*, 2005. **43**(3): p. 309-322.
 143. Muris, P., C. Meesters, and E. Schouten, *A brief questionnaire of DSM-IV-defined anxiety and depression symptoms among children*. *Clinical Psychology & Psychotherapy: An International Journal of Theory & Practice*, 2002. **9**(6): p. 430-442.
 144. Ebesutani, C., et al., *Concurrent validity of the Child Behavior Checklist DSM-oriented scales: Correspondence with DSM diagnoses and comparison to syndrome scales*. *Journal of*

- Psychopathology and Behavioral Assessment, 2010. **32**(3): p. 373-384.
145. Harris, S.K., et al., *Adolescent substance use screening in primary care: Validity of computer self-administered versus clinician-administered screening*. Substance Abuse 2016. **37**(1): p. 197-203.
 146. Knight, J.R., et al., *Validity of Brief Alcohol Screening Tests Among Adolescents: A Comparison of the AUDIT, POSIT, CAGE, and CRAFFT*. Alcoholism: Clinical & Experimental Research, 2003. **27**: p. 67-73.
 147. Koning, I.M., R.J. Van den Eijnden, and W.A. Vollebergh, *Alcohol-specific parenting, adolescents' self-control, and alcohol use: A moderated mediation model*. Journal of studies on alcohol and drugs 2014. **75**(1): p. 16-23.
 148. Spijkerman, R., R.J. Van den Eijnden, and A. Huiberts, *Socioeconomic differences in alcohol-specific parenting practices and adolescents' drinking patterns*. European addiction research, 2008. **14**(1): p. 26-37.
 149. Carver, H., et al., *Parent-child connectedness and communication in relation to alcohol, tobacco and drug use in adolescence: An integrative review of the literature*. Drugs: education, prevention policy Analysis, 2017. **24**(2): p. 119-133.
 150. Hatch, J.A., *Doing qualitative research in education settings*. 2002: Suny Press.
 151. Braun, V. and V.J.Q.r.i.p. Clarke, *Using thematic analysis in psychology*. 2006. **3**(2): p. 77-101.
 152. Corbin, J. and A. Strauss, *Basics of Qualitative Research Techniques and Procedures for Developing Grounded Theory*. 2014: Sage Publications.
 153. Fals-Stewart, W. and G.R. Birchler, *Behavioral couples therapy with alcoholic men and their intimate partners: The comparative effectiveness of bachelor's and master's level counselors*. Behavior Therapy, 2002. **33**: p. 123-147.
 154. Muthen, L. and B. Muthen, *Mplus: Statistical Analysis with Latent Variables, User's Guide*. Fourth ed. 2006, Los Angeles, CA: Muthen & Muthen.
 155. Raudenbush, S. and A. Bryk, *Hierarchical Linear Models: Applications and Data Analysis Methods, Second Edition*. 2002, Thousand Oaks, CA: Sage.
 156. Bates, D., et al., *Package 'lme4'*. URL <http://lme4.r-forge.r-project.org>, 2009.
 157. R Core Team, *R: A language and environment for statistical computing*. 2013.
 158. Collins, L.M., J.L. Schafer, and C.-M. Kam, *A comparison of inclusive and restrictive strategies in modern missing data procedures*. Psychological methods, 2001. **6**(4): p. 330.
 159. Ben-Shachar, M., D. Makowski, and D. Lüdtke, *effectsize: Indices of effect size and standardized parameters (Version 0.4. 5)[Computer software]*. 2021.
 160. Muth, C., et al., *Alternative models for small samples in psychological research: applying linear mixed effects models and generalized estimating equations to repeated measures data*. Educational and psychological measurement, 2016. **76**(1): p. 64-87.
 161. Ehrenreich-May, J., et al., *An initial waitlist-controlled trial of the Unified Protocol for the treatment of emotional disorders in adolescents*. Journal of Anxiety Disorders, 2017. **46**: p. 46-55.
 162. Chorpita, B.F., E.L. Daleiden, and J.R. Weisz, *Modularity in the design and application of therapeutic interventions*. Applied and Preventive Psychology, 2005. **11**: p. 141-156.
 163. Lyon, A., et al., *A case for modular design: Implications for implementing evidence-based interventions with culturally diverse youth*. Professional Psychology: Research and Practice, 2014. **45**(1): p. 57-66.
 164. Wuthrich, V.M., et al., *Effectiveness of psychotherapy for internalising symptoms in children and adolescents when delivered in routine settings: a systematic review and meta-analysis*. Clinical Child and Family Psychology Review, 2023. **26**(3): p. 824-848.
 165. Mental Health Services Administration, C.f.S.A.T., *Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and*

- Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55), in Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. . 2020.*
166. Hogue, A., et al., *Evidence Base on Outpatient Behavioral Treatments for Adolescent Substance Use, 2014-2017: Outcomes, Treatment Delivery, and Promising Horizons*. Journal of Clinical Child & Adolescent Psychology, 2018. **47**(4): p. 499-526.
 167. Weersing, R.V., et al., *Evidence base update of psychosocial treatments for child and adolescent depression*. Journal of Clinical Child & Adolescent Psychology, 2017. **46**: p. 11-43.
 168. Byrne, S., et al., *Do parents enhance cognitive behavior therapy for youth anxiety? An overview of systematic reviews over time*. Clinical Child and Family Psychology Review, 2023. **26**(3): p. 773-788.
 169. Weisz, J.R., et al., *Shrinking the gap between research and practice: Tailoring and testing youth psychotherapies in clinical care contexts*. Annual Review of Clinical Psychology, 2015. **11**: p. 139-163.
 170. Kontopantelis, E., et al., *Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis*. bmj, 2015. **350**.




Figure 1. Protocol Foundations for the Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID): Study Protocol for a Quasi-Experimental Treatment Development Study. ID: Internalizing disorder; CBT: Cognitive-behavioral therapy; SUD: Substance use disorder.




Figure 2. Design and Timeline of Study Activities for the Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID): Study Protocol for a Quasi-Experimental Treatment Development Study. TAU: Treatment as usual.

Preprint
JMIR Publications


Supplementary Files

Untitled.


URL: <http://asset.jmir.pub/assets/79a19d2e07224a0aa3b9848125268237.docx>

Figures

Protocol foundations for the Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID): Study Protocol for a Quasi-Experimental Treatment Development Study. ID: Internalizing disorder; CBT: Cognitive-behavioral therapy; SUD: Substance use disorder.



Design and timeline of study activities for the Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID): Study Protocol for a Quasi-Experimental Treatment Development Study. TAU: Treatment as usual.



Multimedia Appendixes

Sample consent form for Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID): Study Protocol for a Quasi-Experimental Treatment Development Study.

URL: <http://asset.jmir.pub/assets/1f5fcc6603cc3aac2a9bd6842601da56.docx>

Study committees/teams for Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID): Study Protocol for a Quasi-Experimental Treatment Development Study.

URL: <http://asset.jmir.pub/assets/c924755879ed6f521929ead519f55a3e.docx>

Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist for Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID): Study Protocol for a Quasi-Experimental Treatment Development Study.

URL: <http://asset.jmir.pub/assets/84573857ce89d3de91f86c11b866b0b5.docx>

